Navigation Links
Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
Date:9/13/2012

A-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information            

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of po
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
2. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
3. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
4. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
5. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
6. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
7. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
8. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
9. AllCells Introduces Autoimmune Diseased Cells and Tissue Products
10. Stem Cells Bring New Hope for Parry-Romberg Syndrome Patients
11. AllCells, LLC Named to Inc. Magazines 500/5000 List of Fastest Growing Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
(Date:7/29/2015)... July 29, 2015 US-Australian drug discovery company, ... confirmed it is committed to progressing its ground-breaking technology ... practicable and to ensure the Company delivers the best ... Iain Ross , said the Company currently had ... pre-clinical programs, discovery programs and academic partnerships and initiatives, ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation ... largest providers of post-acute healthcare services, offering both ... results of operations for the second quarter ended ... was characterized by strong volume growth in both ... EBITDA," said Jay Grinney, President and Chief Executive ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25
... Cepheid (NASDAQ: CPHD ) today ... Drug Administration (FDA) to market Xpert® Flu . The ... simultaneously detects and differentiates Influenza A, Influenza B, and the ... (Photo:   http://photos.prnewswire.com/prnh/20110426/LA89263 ) "With Xpert ...
... CITY, April 26, 2011 AAPC ( www.aapc.com ) ... 30, and once again lowered prices from the previous year. Prices ... "While the primary purpose of a price reduction was to ... take advantage of the significant savings," said Olga Starynskaya, coding books ...
... MALVERN, Pa., April 25, 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... results for the first quarter 2011 on Monday, May 9, ... Company will also conduct a conference call that day at ... first quarter 2011.  The presentation slides to be used during ...
Cached Biology Technology:Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain 2Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain 3Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain 4AAPC Lowers Prices on Medical Coding Books, Again 2Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011 2Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011 3
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/23/2015)... , July 23, 2015 Research and ... of the "Global Outlook of the Biometrics ... The global biometrics market is ... and commercial applications owing to the uptake of ... a transformation that enhances the growth of biometrics ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... a fatal genetic disorder called Krabbe Disease can be saved ... from umbilical cord blood before symptoms of the disease develop, ... issue of the New England Journal of Medicine. , Without ... to lose all cognitive and motor functions and die by ...
... new 250 million year-old species of large, meat-eating ... from McGill University. Their findings published in today's ... amphibious carnivores from the Republic of Niger in ... carnivores in this area," says McGill paleontologist, and ...
... the hair at the back of the man's head gets ... lesser hair loss. There are hardly any successful counter-measures ?despite ... has long been suspected that hereditary factors are important in ... which genes are involved. The researchers in the team headed ...
Cached Biology News:Infants with Rare Genetic Disease Saved By Cord Blood Stem Cells 2Infants with Rare Genetic Disease Saved By Cord Blood Stem Cells 3Infants with Rare Genetic Disease Saved By Cord Blood Stem Cells 4Tendency to hair loss inherited from the mother 2
1+ mg expected yield of purified protein, expressed in insect cells - excludes cDNA...
...
Request Info...
... Cultrex High Protein Concentration Basement ... for use in in vivo applications ... gelling times, increased gel strength, and ... HC20+ has the advantage of lot-to-lot ...
Biology Products: